Kiniksa appoints M. Cantey Boyd to Board, increasing size to 10 directors

Kiniksa Pharmaceuticals International, plc

Board size increased from 9 to 10; Boyd appointed as Class III director.
Boyd is a Managing Director at Baker Bros. Advisors LP, a life sciences investment firm.
She will serve on Compensation Committee; receives standard non-employee director compensation.
No material transactions between Boyd and the company; standard indemnification agreement entered.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

M. Cantey Boyd

Director

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2024-10-04
Filed: October 7, 2024, 7:59 PM ET

the appointment of M. Cantey Boyd, age 44, to the Board to fill the vacancy created thereby

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

M. Cantey Boyd was appointed as Director at Kiniksa Pharmaceuticals International, plc.

Action: appointed
Role: Director

Exact text from the filing

the appointment of M. Cantey Boyd, age 44, to the Board to fill the vacancy created thereby

View on SEC.gov

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-24-106690

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.